fenofibrate (Antara, Fenoglide, Fibricor, Lipofen, Lofibra, Tricor, Triglide, Trilipix)

  • Pharmacy Author:
    Omudhome Ogbru, PharmD

    Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.

  • Medical and Pharmacy Editor: Jay W. Marks, MD
    Jay W. Marks, MD

    Jay W. Marks, MD

    Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.

View the Cholesterol Levels Slideshow Pictures

DOSING:

Hypertriglyceridemia

  • Antara: 43-130 mg orally once daily
  • Fenoglide: 40-120 mg orally once daily
  • Fibricor: 35-105 mg orally once daily
  • Lipofen: 50-150 mg orally once daily
  • Lofibra: 67-200 mg orally once daily
  • Tricor: 48-145 mg orally once daily
  • Triglide: 50-160 mg orally once daily
  • Triliprix: 45-135 mg orally once daily

Hypercholesterolemia or mixed hyperlipidemia

  • Antara: 130 mg orally once daily
  • Fenoglide: 120 mg orally once daily
  • Fibricor: 105 mg orally once daily
  • Lipofen: 150 mg orally once daily
  • Lofibra: 160 mg orally once daily
  • Tricor: 145 mg orally once daily
  • Triglide: 160 mg orally once daily
  • Trilipix: 135 mg orally once daily

DRUG INTERACTIONS: Bile acid sequestrants (colestipol [Colestid], cholestyramine [Questran, Questran Light]) may decrease the absorption of fibric acid and reduce their effectiveness.

Fibric acid derivatives may increase the adverse effects of colchicine (Colcrys) on muscle tissue.

Cyclosporine may increase the toxic effects of fibric acid derivatives on the kidney while fibric acid derivatives may decrease blood levels of cyclosporine.

Fenofibrate and its derivatives may increase the adverse effects associated with ezetimibe (Zetia), HMG-CoA reductase inhibitors (statins), and sulfonlyureas. Fibric acid derivatives may increase the anticoagulation (blood-thinning) benefits of warfarin (Coumadin).

Medically Reviewed by a Doctor on 11/11/2014

Quick GuideLower Your Cholesterol, Save Your Heart

Lower Your Cholesterol, Save Your Heart
FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

RxList Logo

Need help identifying pills and medications?

Use the pill identifier tool on RxList.

Subscribe to MedicineNet's Heart Health Newsletter

By clicking Submit, I agree to the MedicineNet's Terms & Conditions & Privacy Policy and understand that I may opt out of MedicineNet's subscriptions at any time.

Health Solutions From Our Sponsors